<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39367276</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-1784</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>04</Day></PubDate></JournalIssue><Title>Nature reviews. Drug discovery</Title><ISOAbbreviation>Nat Rev Drug Discov</ISOAbbreviation></Journal><ArticleTitle>mRNA vaccines for infectious diseases - advances, challenges and opportunities.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41573-024-01042-y</ELocationID><Abstract><AbstractText>The concept of mRNA-based vaccines emerged more than three decades ago. Groundbreaking discoveries and technological advancements over the past 20 years have resolved the major roadblocks that initially delayed application of this new vaccine modality. The rapid development of nucleoside-modified COVID-19 mRNA vaccines demonstrated that this immunization platform is easy to develop, has an acceptable safety profile and can be produced at a large scale. The flexibility and ease of antigen design have enabled mRNA vaccines to enter development for a wide range of viruses as well as for various bacteria and parasites. However, gaps in our knowledge limit the development of next-generation mRNA vaccines with increased potency and safety. A deeper understanding of the mechanisms of action of mRNA vaccines, application of novel technologies enabling rational antigen design, and innovative vaccine delivery strategies and vaccination regimens will likely yield potent novel vaccines against a wide range of pathogens.</AbstractText><CopyrightInformation>© 2024. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pardi</LastName><ForeName>Norbert</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-1008-6242</Identifier><AffiliationInfo><Affiliation>Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. pnorbert@pennmedicine.upenn.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krammer</LastName><ForeName>Florian</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-4121-776X</Identifier><AffiliationInfo><Affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. florian.krammer@mssm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA. florian.krammer@mssm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. florian.krammer@mssm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, Vienna, Austria. florian.krammer@mssm.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Drug Discov</MedlineTA><NlmUniqueID>101124171</NlmUniqueID><ISSNLinking>1474-1776</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>5</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>5</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>23</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39367276</ArticleId><ArticleId IdType="doi">10.1038/s41573-024-01042-y</ArticleId><ArticleId IdType="pii">10.1038/s41573-024-01042-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shattock, A. J. et al. Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization. Lancet 403, 2307–2316 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38705159</ArticleId><ArticleId IdType="pmc">11140691</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(24)00850-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard, A. J. &amp; Bijker, E. M. A guide to vaccinology: from basic principles to new developments. Nat. Rev. Immunol. 21, 83–100 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33353987</ArticleId><ArticleId IdType="doi">10.1038/s41577-020-00479-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Freyn, A. W. et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol. Ther. 28, 1569–1584 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32359470</ArticleId><ArticleId IdType="pmc">7335735</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2020.04.018</ArticleId></ArticleIdList></Reference><Reference><Citation>John, S. et al. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine 36, 1689–1699 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29456015</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2018.01.029</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon, M. et al. Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses. Proc. Natl Acad. Sci. USA 119, e2206333119 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36322769</ArticleId><ArticleId IdType="pmc">9659346</ArticleId><ArticleId IdType="doi">10.1073/pnas.2206333119</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi, N. et al. Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses. Nat. Commun. 13, 4677 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35945226</ArticleId><ArticleId IdType="pmc">9362976</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-32149-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Sajid, A. et al. mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent. Sci. Transl. Med. 13, eabj9827 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34788080</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abj9827</ArticleId></ArticleIdList></Reference><Reference><Citation>Arevalo, C. P. et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science 378, 899–904 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36423275</ArticleId><ArticleId IdType="pmc">10790309</ArticleId><ArticleId IdType="doi">10.1126/science.abm0271</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng, H. F. et al. mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States. Nat. Commun. 14, 5851 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37730701</ArticleId><ArticleId IdType="pmc">10511551</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-41537-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris, E. Combined COVID-19, flu vaccine candidate headed to phase 3 trials. JAMA 330, 2044 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37966868</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye, Q. et al. Rational development of a combined mRNA vaccine against COVID-19 and influenza. NPJ Vaccines 7, 84 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35882870</ArticleId><ArticleId IdType="pmc">9315335</ArticleId><ArticleId IdType="doi">10.1038/s41541-022-00478-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniel, S., Kis, Z., Kontoravdi, C. &amp; Shah, N. Quality by design for enabling RNA platform production processes. Trends Biotechnol. 40, 1213–1228 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35491266</ArticleId><ArticleId IdType="doi">10.1016/j.tibtech.2022.03.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Warne, N. et al. Delivering 3 billion doses of Comirnaty in 2021. Nat. Biotechnol. 41, 183–188 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36732478</ArticleId></ArticleIdList></Reference><Reference><Citation>Alameh, M. G., Weissman, D. &amp; Pardi, N. Messenger RNA-based vaccines against infectious diseases. Curr. Top. Microbiol. Immunol. 440, 111–145 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">32300916</ArticleId></ArticleIdList></Reference><Reference><Citation>Blakney, A. K., Ip, S. &amp; Geall, A. J. An update on self-amplifying mRNA vaccine development. Vaccines 9, 97 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33525396</ArticleId><ArticleId IdType="pmc">7911542</ArticleId><ArticleId IdType="doi">10.3390/vaccines9020097</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutz, J. et al. Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines 2, 29 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29263884</ArticleId><ArticleId IdType="pmc">5648897</ArticleId><ArticleId IdType="doi">10.1038/s41541-017-0032-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Petsch, B. et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat. Biotechnol. 30, 1210–1216 (2012). The first published paper demonstrating that a directly injected, non-replicating mRNA vaccine can induce protective immune responses against a viral pathogen.</Citation><ArticleIdList><ArticleId IdType="pubmed">23159882</ArticleId><ArticleId IdType="doi">10.1038/nbt.2436</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch, S. et al. mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. NPJ Vaccines 6, 57 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33863911</ArticleId><ArticleId IdType="pmc">8052455</ArticleId><ArticleId IdType="doi">10.1038/s41541-021-00311-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremsner, P. G. et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet Infect. Dis. 22, 329–340 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34826381</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(21)00677-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021). Along with Polack et al. (2020), the first report about the results of a large phase III clinical trial with an mRNA vaccine.</Citation><ArticleIdList><ArticleId IdType="pubmed">33378609</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020). Along with Baden et al. (2021), the first report about the results of a large phase III clinical trial with an mRNA vaccine.</Citation><ArticleIdList><ArticleId IdType="pubmed">33301246</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariko, K., Buckstein, M., Ni, H. &amp; Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165–175 (2005). The first report showing that nucleoside modification of IVT mRNA decreases its inflammatory capacity.</Citation><ArticleIdList><ArticleId IdType="pubmed">16111635</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2005.06.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariko, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833–1840 (2008). The first report demonstrating that the introduction of modified nucleosides to the IVT mRNA increases its translatability.</Citation><ArticleIdList><ArticleId IdType="pubmed">18797453</ArticleId><ArticleId IdType="doi">10.1038/mt.2008.200</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhary, N., Weissman, D. &amp; Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817–838 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34433919</ArticleId><ArticleId IdType="pmc">8386155</ArticleId><ArticleId IdType="doi">10.1038/s41573-021-00283-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Metkar, M., Pepin, C. S. &amp; Moore, M. J. Tailor made: the art of therapeutic mRNA design. Nat. Rev. Drug Discov. 23, 67–83 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38030688</ArticleId><ArticleId IdType="doi">10.1038/s41573-023-00827-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi, N., Hogan, M. J., Porter, F. W. &amp; Weissman, D. mRNA vaccines — a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29326426</ArticleId><ArticleId IdType="pmc">5906799</ArticleId><ArticleId IdType="doi">10.1038/nrd.2017.243</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbeke, R., Hogan, M. J., Lore, K. &amp; Pardi, N. Innate immune mechanisms of mRNA vaccines. Immunity 55, 1993–2005 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36351374</ArticleId><ArticleId IdType="pmc">9641982</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2022.10.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson, J. M. et al. Cap 1 messenger RNA synthesis with co-transcriptional CleanCap<sup>(R)</sup> analog by in vitro transcription. Curr. Protoc. 1, e39 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33524237</ArticleId><ArticleId IdType="doi">10.1002/cpz1.39</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi, N., Muramatsu, H., Weissman, D. &amp; Kariko, K. In vitro transcription of long RNA containing modified nucleosides. Methods Mol. Biol. 969, 29–42 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23296925</ArticleId><ArticleId IdType="doi">10.1007/978-1-62703-260-5_2</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas, Y. M. et al. Structure of human IFIT1 with capped RNA reveals adaptable mRNA binding and mechanisms for sensing N1 and N2 ribose 2′-O methylations. Proc. Natl Acad. Sci. USA 114, E2106–E2115 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28251928</ArticleId><ArticleId IdType="pmc">5358387</ArticleId><ArticleId IdType="doi">10.1073/pnas.1612444114</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo-Hair, S. M. &amp; Seelig, G. Machine learning for designing next-generation mRNA therapeutics. Acc. Chem. Res. 55, 24–34 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34905691</ArticleId><ArticleId IdType="doi">10.1021/acs.accounts.1c00621</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu, Y. et al. A 5′ UTR language model for decoding untranslated regions of mRNA and function predictions. Nat. Mach. Intell. 6, 449–460 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38855263</ArticleId><ArticleId IdType="doi">10.1038/s42256-024-00823-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia, L. et al. Decoding mRNA translatability and stability from the 5′ UTR. Nat. Struct. Mol. Biol. 27, 814–821 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32719458</ArticleId><ArticleId IdType="doi">10.1038/s41594-020-0465-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Leppek, K. et al. Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. Nat. Commun. 13, 1536 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35318324</ArticleId><ArticleId IdType="pmc">8940940</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-28776-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauger, D. M. et al. mRNA structure regulates protein expression through changes in functional half-life. Proc. Natl Acad. Sci. USA 116, 24075–24083 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31712433</ArticleId><ArticleId IdType="pmc">6883848</ArticleId><ArticleId IdType="doi">10.1073/pnas.1908052116</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, H. et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature 621, 396–403 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37130545</ArticleId><ArticleId IdType="pmc">10499610</ArticleId><ArticleId IdType="doi">10.1038/s41586-023-06127-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudla, G., Lipinski, L., Caffin, F., Helwak, A. &amp; Zylicz, M. High guanine and cytosine content increases mRNA levels in mammalian cells. PLoS Biol. 4, e180 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16700628</ArticleId><ArticleId IdType="pmc">1463026</ArticleId><ArticleId IdType="doi">10.1371/journal.pbio.0040180</ArticleId></ArticleIdList></Reference><Reference><Citation>Svitkin, Y. V. et al. N<sup>1</sup>-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density. Nucleic Acids Res. 45, 6023–6036 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28334758</ArticleId><ArticleId IdType="pmc">5449617</ArticleId><ArticleId IdType="doi">10.1093/nar/gkx135</ArticleId></ArticleIdList></Reference><Reference><Citation>Andries, O. et al. N<sup>1</sup>-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J. Control. Rel. 217, 337–344 (2015). The first study evaluating the widely used N<sup>1</sup>-methylpseudouridine-containing mRNA in vitro and in vivo.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2015.08.051</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanji, H. et al. Toll-like receptor 8 senses degradation products of single-stranded RNA. Nat. Struct. Mol. Biol. 22, 109–115 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25599397</ArticleId><ArticleId IdType="doi">10.1038/nsmb.2943</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Z. et al. Structural analysis reveals that toll-like receptor 7 is a dual receptor for guanosine and single-stranded RNA. Immunity 45, 737–748 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27742543</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2016.09.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Baiersdorfer, M. et al. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids 15, 26–35 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30933724</ArticleId><ArticleId IdType="pmc">6444222</ArticleId><ArticleId IdType="doi">10.1016/j.omtn.2019.02.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster, J. B. et al. Purification of mRNA encoding chimeric antigen receptor is critical for generation of a robust T-cell response. Hum. Gene Ther. 30, 168–178 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30024272</ArticleId><ArticleId IdType="pmc">6383579</ArticleId><ArticleId IdType="doi">10.1089/hum.2018.145</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariko, K., Muramatsu, H., Ludwig, J. &amp; Weissman, D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 39, e142 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21890902</ArticleId><ArticleId IdType="pmc">3241667</ArticleId><ArticleId IdType="doi">10.1093/nar/gkr695</ArticleId></ArticleIdList></Reference><Reference><Citation>Dousis, A., Ravichandran, K., Hobert, E. M., Moore, M. J. &amp; Rabideau, A. E. An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts. Nat. Biotechnol. 41, 560–568 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36357718</ArticleId><ArticleId IdType="doi">10.1038/s41587-022-01525-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Devarkar, S. C. et al. Structural basis for m7G recognition and 2′-O-methyl discrimination in capped RNAs by the innate immune receptor RIG-I. Proc. Natl Acad. Sci. USA 113, 596–601 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26733676</ArticleId><ArticleId IdType="pmc">4725518</ArticleId><ArticleId IdType="doi">10.1073/pnas.1515152113</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson, J. et al. Impact of mRNA chemistry and manufacturing process on innate immune activation. Sci. Adv. 6, eaaz6893 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32637598</ArticleId><ArticleId IdType="pmc">7314518</ArticleId><ArticleId IdType="doi">10.1126/sciadv.aaz6893</ArticleId></ArticleIdList></Reference><Reference><Citation>Geall, A. J. et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl Acad. Sci. USA 109, 14604–14609 (2012). This is the first study that uses LNPs for RNA vaccine delivery.</Citation><ArticleIdList><ArticleId IdType="pubmed">22908294</ArticleId><ArticleId IdType="pmc">3437863</ArticleId><ArticleId IdType="doi">10.1073/pnas.1209367109</ArticleId></ArticleIdList></Reference><Reference><Citation>Low, J. G. et al. A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine. NPJ Vaccines 7, 161 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36513697</ArticleId><ArticleId IdType="pmc">9745278</ArticleId><ArticleId IdType="doi">10.1038/s41541-022-00590-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollock, K. M. et al. Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. EClinicalMedicine 44, 101262 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35043093</ArticleId><ArticleId IdType="pmc">8759012</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2021.101262</ArticleId></ArticleIdList></Reference><Reference><Citation>Oda, Y. et al. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet Infect. Dis. 24, 351–360 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38141632</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(23)00650-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolgin, E. Self-copying RNA vaccine wins first full approval: what’s next? Nature 624, 236–237 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">38057473</ArticleId><ArticleId IdType="doi">10.1038/d41586-023-03859-w</ArticleId></ArticleIdList></Reference><Reference><Citation>McGee, J. E. et al. Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency. Nat. Biotechnol. https://doi.org/10.1038/s41587-024-02306-z (2024). The first study providing comparative data on nucleoside-modified saRNA vaccines.</Citation></Reference><Reference><Citation>Beissert, T. et al. A trans-amplifying RNA vaccine strategy for induction of potent protective immunity. Mol. Ther. 28, 119–128 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31624015</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2019.09.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Blakney, A. K., McKay, P. F. &amp; Shattock, R. J. Structural components for amplification of positive and negative strand VEEV splitzicons. Front. Mol. Biosci. 5, 71 (2018). The first study that describes a bipartite RNA-based delivery platform.</Citation><ArticleIdList><ArticleId IdType="pubmed">30094239</ArticleId><ArticleId IdType="pmc">6070733</ArticleId><ArticleId IdType="doi">10.3389/fmolb.2018.00071</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkovic, M. et al. A trans-amplifying RNA simplified to essential elements is highly replicative and robustly immunogenic in mice. Mol. Ther. 31, 1636–1646 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36694464</ArticleId><ArticleId IdType="pmc">10277886</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2023.01.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou, X., Zaks, T., Langer, R. &amp; Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078–1094 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34394960</ArticleId><ArticleId IdType="pmc">8353930</ArticleId><ArticleId IdType="doi">10.1038/s41578-021-00358-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullis, P. R. &amp; Hope, M. J. Lipid nanoparticle systems for enabling gene therapies. Mol. Ther. 25, 1467–1475 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28412170</ArticleId><ArticleId IdType="pmc">5498813</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2017.03.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi, N. et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J. Control. Rel. 217, 345–351 (2015). The first study that uses LNPs for nucleoside-modified mRNA delivery.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2015.08.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Semple, S. C. et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28, 172–176 (2010). The first detailed study that uses LNPs for in vivo RNA delivery.</Citation><ArticleIdList><ArticleId IdType="pubmed">20081866</ArticleId><ArticleId IdType="doi">10.1038/nbt.1602</ArticleId></ArticleIdList></Reference><Reference><Citation>Alameh, M. G. et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 54, 2877–2892 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34852217</ArticleId><ArticleId IdType="pmc">8566475</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2021.11.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahtinen, S. et al. IL-1 and IL-1Ra are key regulators of the inflammatory response to RNA vaccines. Nat. Immunol. 23, 532–542 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35332327</ArticleId><ArticleId IdType="doi">10.1038/s41590-022-01160-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldeon Vaca, G. et al. Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection. Sci. Adv. 9, eadh1655 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37738334</ArticleId><ArticleId IdType="pmc">10516494</ArticleId><ArticleId IdType="doi">10.1126/sciadv.adh1655</ArticleId></ArticleIdList></Reference><Reference><Citation>Erasmus, J. H. et al. A nanostructured lipid carrier for delivery of a replicating viral RNA provides single, low-dose protection against Zika. Mol. Ther. 26, 2507–2522 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30078765</ArticleId><ArticleId IdType="pmc">6171036</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2018.07.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Erasmus, J. H. et al. An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. Sci. Transl. Med. 12, eabc9396 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32690628</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abc9396</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen, S. E. et al. An RNA-based vaccine platform for use against mycobacterium tuberculosis. Vaccines 11, 130 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36679975</ArticleId><ArticleId IdType="pmc">9862644</ArticleId><ArticleId IdType="doi">10.3390/vaccines11010130</ArticleId></ArticleIdList></Reference><Reference><Citation>Leventhal, S. S. et al. Replicating RNA vaccination elicits an unexpected immune response that efficiently protects mice against lethal Crimean-Congo hemorrhagic fever virus challenge. Ebiomedicine 82, 104188 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35907368</ArticleId><ArticleId IdType="pmc">9335360</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2022.104188</ArticleId></ArticleIdList></Reference><Reference><Citation>MacMillen, Z. et al. Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine. NPJ Vaccines 9, 12 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38200025</ArticleId><ArticleId IdType="pmc">10781674</ArticleId><ArticleId IdType="doi">10.1038/s41541-023-00799-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Bus, T. Traeger, A. Schubert, U. S. The great escape: how cationic polyplexes overcome the endosomal barrier. J. Mater. Chem. B6, 6904 6918 (2018).</Citation></Reference><Reference><Citation>Démoulins, T. et al. Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines. Nanomed. Nanotechnol. 12, 711–722 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nano.2015.11.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghimi, S. M. et al. A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol. Ther. 11, 990–995 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15922971</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2005.02.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Chahal, J. S. et al. An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8<sup>+</sup> T cell responses in a mouse model. Sci. Rep. 7, 252 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28325910</ArticleId><ArticleId IdType="pmc">5427874</ArticleId><ArticleId IdType="doi">10.1038/s41598-017-00193-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Chahal, J. S. et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc. Natl Acad. Sci. USA 113, E4133–E4142 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27382155</ArticleId><ArticleId IdType="pmc">4961123</ArticleId><ArticleId IdType="doi">10.1073/pnas.1600299113</ArticleId></ArticleIdList></Reference><Reference><Citation>Suberi, A. et al. Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination. Sci. Transl. Med. 15, eabq0603 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37585505</ArticleId><ArticleId IdType="pmc">11137749</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abq0603</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang, Y. et al. Quantitating endosomal escape of a library of polymers for mRNA delivery. Nano Lett. 20, 1117–1123 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32003222</ArticleId><ArticleId IdType="pmc">7195212</ArticleId><ArticleId IdType="doi">10.1021/acs.nanolett.9b04426</ArticleId></ArticleIdList></Reference><Reference><Citation>Grun, M. K. et al. PEGylation of poly(amine-co-ester) polyplexes for tunable gene delivery. Biomaterials 272, 120780 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33813260</ArticleId><ArticleId IdType="pmc">8085770</ArticleId><ArticleId IdType="doi">10.1016/j.biomaterials.2021.120780</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassett, K. J. et al. mRNA vaccine trafficking and resulting protein expression after intramuscular administration. Mol. Ther. Nucleic Acids 35, 102083 (2024). Well-conducted study describing the biodistribution of mRNA and mRNA-based expression in vivo in NHPs.</Citation><ArticleIdList><ArticleId IdType="pubmed">38161733</ArticleId><ArticleId IdType="doi">10.1016/j.omtn.2023.102083</ArticleId></ArticleIdList></Reference><Reference><Citation>Roltgen, K. et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell 185, 1025–1040 (2022). A nice study that includes characterization of germinal centre formation after COVID-19 mRNA vaccination in humans.</Citation><ArticleIdList><ArticleId IdType="pubmed">35148837</ArticleId><ArticleId IdType="pmc">8786601</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2022.01.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellgren, F. et al. Modulation of innate immune response to mRNA vaccination after SARS-CoV-2 infection or sequential vaccination in humans. JCI Insight 9, e175401 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38716734</ArticleId><ArticleId IdType="pmc">11141904</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.175401</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang, F. et al. Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. Mol. Ther. 25, 2635–2647 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28958578</ArticleId><ArticleId IdType="pmc">5768558</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2017.08.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay, K. E. et al. Visualization of early events in mRNA vaccine delivery in non-human primates via PET-CT and near-infrared imaging. Nat. Biomed. Eng. 3, 371–380 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30936432</ArticleId><ArticleId IdType="doi">10.1038/s41551-019-0378-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito, L. A. et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol. Ther. 22, 2118–2129 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25027661</ArticleId><ArticleId IdType="pmc">4429691</ArticleId><ArticleId IdType="doi">10.1038/mt.2014.133</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazzaro, S. et al. CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes. Immunology 146, 312–326 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26173587</ArticleId><ArticleId IdType="pmc">4582972</ArticleId><ArticleId IdType="doi">10.1111/imm.12505</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 596, 109–113 (2021). An important study that shows long-lasting germinal centres in humans after mRNA vaccination.</Citation><ArticleIdList><ArticleId IdType="pubmed">34182569</ArticleId><ArticleId IdType="pmc">8935394</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03738-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Laidlaw, B. J. &amp; Ellebedy, A. H. The germinal centre B cell response to SARS-CoV-2. Nat. Rev. Immunol. 22, 7–18 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34873279</ArticleId><ArticleId IdType="doi">10.1038/s41577-021-00657-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, W. et al. Germinal centre-driven maturation of B cell response to mRNA vaccination. Nature 604, 141–145 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35168246</ArticleId><ArticleId IdType="pmc">9204750</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04527-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano, K. et al. SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals. Nat. Commun. 13, 5135 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36050304</ArticleId><ArticleId IdType="pmc">9435409</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-32389-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyaka, P. N. Inducing mucosal IgA: a challenge for vaccine adjuvants and delivery systems. J. Immunol. 199, 9–16 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28630108</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1601775</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma, P., Hoorn, D., Aitha, A., Breier, D. &amp; Peer, D. The immunostimulatory nature of mRNA lipid nanoparticles. Adv. Drug Deliv. Rev. 205, 115175 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38218350</ArticleId><ArticleId IdType="doi">10.1016/j.addr.2023.115175</ArticleId></ArticleIdList></Reference><Reference><Citation>Omo-Lamai, S. et al. Lipid nanoparticle-associated inflammation is triggered by sensing of endosomal damage: engineering endosomal escape without side effects. Preprint at bioRxiv https://doi.org/10.1101/2024.04.16.589801 (2024).</Citation></Reference><Reference><Citation>Li, C. et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat. Immunol. 23, 543–555 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35288714</ArticleId><ArticleId IdType="pmc">8989677</ArticleId><ArticleId IdType="doi">10.1038/s41590-022-01163-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam, P. S. et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature 596, 410–416 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34252919</ArticleId><ArticleId IdType="pmc">8761119</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03791-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan, M. J. &amp; Pardi, N. mRNA vaccines in the COVID-19 pandemic and beyond. Annu. Rev. Med. 73, 17–39 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34669432</ArticleId><ArticleId IdType="doi">10.1146/annurev-med-042420-112725</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabo, G. T., Mahiny, A. J. &amp; Vlatkovic, I. COVID-19 mRNA vaccines: platforms and current developments. Mol. Ther. 30, 1850–1868 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35189345</ArticleId><ArticleId IdType="pmc">8856755</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2022.02.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Scorza, F. B. &amp; Pardi, N. New kids on the block: RNA-based influenza virus vaccines. Vaccines 6, 20 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29614788</ArticleId><ArticleId IdType="pmc">6027361</ArticleId><ArticleId IdType="doi">10.3390/vaccines6020020</ArticleId></ArticleIdList></Reference><Reference><Citation>Flynn, J. A. et al. Characterization of humoral and cell-mediated immunity induced by mRNA vaccines expressing influenza hemagglutinin stem and nucleoprotein in mice and nonhuman primates. Vaccine 40, 4412–4423 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35680500</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2022.03.063</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman, R. A. et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine 37, 3326–3334 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31079849</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2019.04.074</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, I. T. et al. Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis. Nat. Commun. 14, 3631 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37336877</ArticleId><ArticleId IdType="pmc">10279702</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-39376-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Moderna. Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, A Seasonal Influenza Vaccine Candidate. moderna https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-Interim-Phase-3-Safety-and-Immunogenicity-Results-for-mRNA-1010-a-Seasonal-Influenza-Vaccine-Candidate/default.aspx (2023).</Citation></Reference><Reference><Citation>Langedijk, A. C. &amp; Bont, L. J. Respiratory syncytial virus infection and novel interventions. Nat. Rev. Microbiol. 21, 734–749 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37438492</ArticleId><ArticleId IdType="doi">10.1038/s41579-023-00919-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Crank, M. C. et al. A proof of concept for structure-based vaccine design targeting RSV in humans. Science 365, 505–509 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31371616</ArticleId><ArticleId IdType="doi">10.1126/science.aav9033</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. Respiratory Syncytial Virus (RSV). FDA.gov https://www.fda.gov/consumers/covid-19-flu-and-rsv/respiratory-syncytial-virus-rsv (2024).</Citation></Reference><Reference><Citation>Espeseth, A. S. et al. Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection. NPJ Vaccines 5, 16 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32128257</ArticleId><ArticleId IdType="pmc">7021756</ArticleId><ArticleId IdType="doi">10.1038/s41541-020-0163-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliprantis, A. O. et al. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Hum. Vaccin. Immunother. 17, 1248–1261 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33121346</ArticleId><ArticleId IdType="doi">10.1080/21645515.2020.1829899</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson, E. et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N. Engl. J. Med. 389, 2233–2244 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">38091530</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2307079</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullard, A. FDA approves mRNA-based RSV vaccine. Nat. Rev. Drug Discov. 23, 487 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38849520</ArticleId></ArticleIdList></Reference><Reference><Citation>August, A. et al. Safety and immunogenicity of an mRNA-based human metapneumovirus and parainfluenza virus type 3 combined vaccine in healthy adults. Open Forum Infect. Dis. 9, ofac206 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35794943</ArticleId><ArticleId IdType="pmc">9251669</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofac206</ArticleId></ArticleIdList></Reference><Reference><Citation>UNAIDS. Fact Sheet. UNAIDS.org https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf (2024).</Citation></Reference><Reference><Citation>Haynes, B. F. et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat. Rev. Immunol. 23, 142–158 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">35962033</ArticleId><ArticleId IdType="doi">10.1038/s41577-022-00753-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Melo, M. et al. Immunogenicity of RNA replicons encoding HIV Env immunogens designed for self-assembly into nanoparticles. Mol. Ther. 27, 2080–2090 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31515132</ArticleId><ArticleId IdType="pmc">6904793</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2019.08.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Melzi, E. et al. Membrane-bound mRNA immunogens lower the threshold to activate HIV Env V2 apex-directed broadly neutralizing B cell precursors in humanized mice. Immunity 55, 2168–2186.e6 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36179690</ArticleId><ArticleId IdType="pmc">9671093</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2022.09.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyo, N. et al. Tetravalent immunogen assembled from conserved regions of HIV-1 and delivered as mRNA demonstrates potent preclinical T-cell immunogenicity and breadth. Vaccines 8, 360 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32640600</ArticleId><ArticleId IdType="pmc">7563622</ArticleId><ArticleId IdType="doi">10.3390/vaccines8030360</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu, Z. K. et al. mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. Cell Rep. 38, 110514 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35294883</ArticleId><ArticleId IdType="pmc">8922439</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2022.110514</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders, K. O. et al. Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. NPJ Vaccines 6, 50 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33837212</ArticleId><ArticleId IdType="pmc">8035178</ArticleId><ArticleId IdType="doi">10.1038/s41541-021-00307-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, P. et al. A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nat. Med. 27, 2234–2245 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34887575</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01574-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Steichen, J. M. et al. HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies. Immunity 45, 483–496 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27617678</ArticleId><ArticleId IdType="pmc">5040827</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2016.08.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta, S. Langenburg, K. T. A perspective on current flavivirus vaccine development: a brief review. Viruses 15, 860 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37112840</ArticleId><ArticleId IdType="pmc">10142581</ArticleId><ArticleId IdType="doi">10.3390/v15040860</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson, T. C. &amp; Diamond, M. S. The continued threat of emerging flaviviruses. Nat. Microbiol. 5, 796–812 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32367055</ArticleId><ArticleId IdType="pmc">7696730</ArticleId><ArticleId IdType="doi">10.1038/s41564-020-0714-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543, 248–251 (2017). Along with Richner et al. (2017), the first study evaluating the immunogenicity and protective efficacy of a nucleoside-modified mRNA-LNP vaccine in animal models.</Citation><ArticleIdList><ArticleId IdType="pubmed">28151488</ArticleId><ArticleId IdType="pmc">5344708</ArticleId><ArticleId IdType="doi">10.1038/nature21428</ArticleId></ArticleIdList></Reference><Reference><Citation>Richner, J. M. et al. Modified mRNA vaccines protect against Zika virus infection. Cell 168, 1114–1125.e10 (2017). Along with Pardi et al. (Nature, 2017), the first study evaluating the immunogenicity and protective efficacy of a nucleoside-modified mRNA-LNP vaccine in animals.</Citation><ArticleIdList><ArticleId IdType="pubmed">28222903</ArticleId><ArticleId IdType="pmc">5388441</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2017.02.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina-Magues, L. G. et al. Immunogenicity and protective activity of mRNA vaccine candidates against yellow fever virus in animal models. NPJ Vaccines 8, 31 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36871059</ArticleId><ArticleId IdType="pmc">9984760</ArticleId><ArticleId IdType="doi">10.1038/s41541-023-00629-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Wollner, C. J. &amp; Richner, J. M. mRNA vaccines against flaviviruses. Vaccines 9, 148 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33673131</ArticleId><ArticleId IdType="pmc">7918459</ArticleId><ArticleId IdType="doi">10.3390/vaccines9020148</ArticleId></ArticleIdList></Reference><Reference><Citation>Bollman, B. et al. An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection. NPJ Vaccines 8, 58 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37080988</ArticleId><ArticleId IdType="pmc">10119314</ArticleId><ArticleId IdType="doi">10.1038/s41541-023-00656-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Essink, B. et al. The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials. Lancet Infect. Dis. 23, 621–633 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36682364</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(22)00764-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz, E., Moreno, N., Peralta, P. H. &amp; Tesh, R. B. A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection. Am. J. Trop. Med. Hyg. 39, 312–314 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">2845825</ArticleId><ArticleId IdType="doi">10.4269/ajtmh.1988.39.312</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer, M. et al. Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease. J. Infect. Dis. 217, 451–455 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29281112</ArticleId><ArticleId IdType="doi">10.1093/infdis/jix592</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronk, A. J. et al. A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection. Nat. Commun. 14, 5603 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37699929</ArticleId><ArticleId IdType="pmc">10497546</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-41376-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelberg, S. et al. Nucleoside-modified mRNA vaccines protect IFNAR<sup>−/−</sup> mice against Crimean-Congo hemorrhagic fever virus infection. J. Virol. 96, e0156821 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34817199</ArticleId><ArticleId IdType="doi">10.1128/jvi.01568-21</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, D. et al. SFTSV Gn-Head mRNA vaccine confers efficient protection against lethal viral challenge. J. Med. Virol. 95, e29203 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37909776</ArticleId><ArticleId IdType="doi">10.1002/jmv.29203</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo, M. K. et al. Evaluation of a single-dose nucleoside-modified messenger RNA vaccine encoding hendra virus-soluble glycoprotein against lethal Nipah virus challenge in Syrian hamsters. J. Infect. Dis. 221, S493–S498 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31751453</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiz553</ArticleId></ArticleIdList></Reference><Reference><Citation>Loomis, R. J. et al. Chimeric fusion (F) and attachment (G) glycoprotein antigen delivery by mRNA as a candidate Nipah vaccine. Front. Immunol. 12, 772864 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34956199</ArticleId><ArticleId IdType="pmc">8692728</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2021.772864</ArticleId></ArticleIdList></Reference><Reference><Citation>Freyn, A. W. et al. An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge. Sci. Transl. Med. 15, eadg3540 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37792954</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.adg3540</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou, F. et al. mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge. Nat. Commun. 14, 5925 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37739969</ArticleId><ArticleId IdType="pmc">10516993</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-41628-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuiani, A. et al. A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease. Cell 187, 1363–1373 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38366591</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2024.01.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai, S. et al. A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice. Front. Immunol. 13, 1099991 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36761167</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.1099991</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellgren, F. et al. Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses. Nat. Commun. 14, 3713 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37349310</ArticleId><ArticleId IdType="pmc">10287699</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-39421-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldrich, C. et al. Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial. Vaccine 39, 1310–1318 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33487468</ArticleId><ArticleId IdType="pmc">7825876</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2020.12.070</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson, C. S. et al. Human cytomegalovirus glycoprotein B nucleoside-modified mRNA vaccine elicits antibody responses with greater durability and breadth than MF59-adjuvanted gB protein immunization. J. Virol. 94, e00186-20 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32051265</ArticleId><ArticleId IdType="pmc">7163130</ArticleId><ArticleId IdType="doi">10.1128/JVI.00186-20</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, H. Y. et al. Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth. NPJ Vaccines 9, 38 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38378950</ArticleId><ArticleId IdType="pmc">10879498</ArticleId><ArticleId IdType="doi">10.1038/s41541-024-00821-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster, H. et al. Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models. Vaccine 39, 5358–5367 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34393017</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2021.08.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, X. T. et al. Human cytomegalovirus mRNA-1647 vaccine candidate elicits potent and broad neutralization and higher antibody-dependent cellular cytotoxicity responses than the gB/MF59 vaccine. J. Infect. Dis. 7, jiad593 (2024).</Citation></Reference><Reference><Citation>Awasthi, S. et al. Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes. Sci. Immunol. 4, aaw7083 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.aaw7083</ArticleId></ArticleIdList></Reference><Reference><Citation>Awasthi, S. et al. Trivalent nucleoside-modified mRNA vaccine yields durable memory B cell protection against genital herpes in preclinical models. J. Clin. Invest. 131, e152310 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34618692</ArticleId><ArticleId IdType="pmc">8631595</ArticleId><ArticleId IdType="doi">10.1172/JCI152310</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan, K. P. et al. An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection. PLoS Pathog. 16, e1008795 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32716975</ArticleId><ArticleId IdType="pmc">7410331</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1008795</ArticleId></ArticleIdList></Reference><Reference><Citation>LaTourette, P. C. 2nd et al. Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine. Vaccine 38, 7409–7413 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33041105</ArticleId><ArticleId IdType="pmc">7545304</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2020.09.079</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, H. et al. A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression. NPJ Vaccines 9, 22 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38310094</ArticleId><ArticleId IdType="pmc">10838333</ArticleId><ArticleId IdType="doi">10.1038/s41541-024-00813-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Patra, T. et al. Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity. NPJ Vaccines 8, 42 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36934116</ArticleId><ArticleId IdType="pmc">10024013</ArticleId><ArticleId IdType="doi">10.1038/s41541-023-00635-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, G. X. et al. mRNA-based vaccines targeting the T-cell epitope-rich domain of epstein barr virus latent proteins elicit robust anti-tumor immunity in mice. Adv. Sci. 10, e2302116 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202302116</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng, X. et al. A synergistic lipid nanoparticle encapsulating mRNA shingles vaccine induces potent immune responses and protects guinea pigs from viral challenges. Adv. Mater. 36, e2310886 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38145557</ArticleId><ArticleId IdType="doi">10.1002/adma.202310886</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, L. et al. Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques. Emerg. Microbes Infect. 13, 2309985 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38258878</ArticleId><ArticleId IdType="pmc">10860463</ArticleId><ArticleId IdType="doi">10.1080/22221751.2024.2309985</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik, K. et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 375, 296–301 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35025605</ArticleId><ArticleId IdType="doi">10.1126/science.abj8222</ArticleId></ArticleIdList></Reference><Reference><Citation>Telford, J. L. Bacterial genome variability and its impact on vaccine design. Cell Host Microbe 3, 408–416 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18541217</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2008.05.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterloh, A. Vaccination against bacterial infections: challenges, progress, and new approaches with a focus on intracellular bacteria. Vaccines 10, 751 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35632507</ArticleId><ArticleId IdType="pmc">9144739</ArticleId><ArticleId IdType="doi">10.3390/vaccines10050751</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzi, J. C. C. et al. Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosis. BMC Biotechnol. 10, 77 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20961459</ArticleId><ArticleId IdType="pmc">2972232</ArticleId><ArticleId IdType="doi">10.1186/1472-6750-10-77</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer, T. F. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin. Infect. Dis. 31 (Suppl. 3), S64–S67 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11010824</ArticleId><ArticleId IdType="doi">10.1086/314072</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruggi, G. et al. Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. Vaccine 35, 361–368 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27939014</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2016.11.040</ArticleId></ArticleIdList></Reference><Reference><Citation>Kon, E. et al. A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium. Sci. Adv. 9, eadg1036 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36888708</ArticleId><ArticleId IdType="pmc">9995031</ArticleId><ArticleId IdType="doi">10.1126/sciadv.adg1036</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer, R. L. et al. Immunopeptidomics-based design of mRNA vaccine formulations against Listeria monocytogenes. Nat. Commun. 13, 6075 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36241641</ArticleId><ArticleId IdType="pmc">9562072</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-33721-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, X. et al. Strong immune responses and protection of PcrV and OprF-I mRNA vaccine candidates against Pseudomonas aeruginosa. NPJ Vaccines 8, 76 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37231060</ArticleId><ArticleId IdType="pmc">10209580</ArticleId><ArticleId IdType="doi">10.1038/s41541-023-00672-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Pine, M. et al. Development of an mRNA-lipid nanoparticle vaccine against Lyme disease. Mol. Ther. 31, 2702–2714 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37533256</ArticleId><ArticleId IdType="pmc">10492027</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2023.07.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Matias, J. et al. mRNA vaccination of rabbits alters the fecundity, but not the attachment, of adult Ixodes scapularis. Sci. Rep. 14, 496 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38177212</ArticleId><ArticleId IdType="pmc">10766947</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-50389-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Matias, J. et al. Specific mRNA lipid nanoparticles and acquired resistance to ticks. Vaccine 41, 4996–5002 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37407406</ArticleId><ArticleId IdType="pmc">10530371</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2023.06.081</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotez, P. &amp; Herricks, J. One Million Deaths by Parasites. PLOS https://speakingofmedicine.plos.org/2015/01/16/one-million-deaths-parasites/ (2015).</Citation></Reference><Reference><Citation>Duthie, M. S. et al. Heterologous immunization with defined RNA and subunit vaccines enhances T cell responses that protect against Leishmania donovani. Front. Immunol. 9, 2420 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30386348</ArticleId><ArticleId IdType="pmc">6199377</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2018.02420</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeson, J. G. et al. Challenges and strategies for developing efficacious and long-lasting malaria vaccines. Sci. Transl. Med. 11, eaau1458 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30626712</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aau1458</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy, P. E. Current approaches to malaria vaccines. Curr. Opin. Microbiol. 70, 102227 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36343566</ArticleId><ArticleId IdType="pmc">11127243</ArticleId><ArticleId IdType="doi">10.1016/j.mib.2022.102227</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi, C. T. H. et al. mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum. NPJ Vaccines 7, 155 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36456563</ArticleId><ArticleId IdType="pmc">9715627</ArticleId><ArticleId IdType="doi">10.1038/s41541-022-00577-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallory, K. L. et al. Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice. NPJ Vaccines 6, 84 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34145286</ArticleId><ArticleId IdType="pmc">8213722</ArticleId><ArticleId IdType="doi">10.1038/s41541-021-00345-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj, D. K. et al. Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria. Nature 582, 104–108 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32427965</ArticleId><ArticleId IdType="pmc">7372601</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2220-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaria, P. V. et al. mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response. NPJ Vaccines 9, 9 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38184666</ArticleId><ArticleId IdType="pmc">10771442</ArticleId><ArticleId IdType="doi">10.1038/s41541-023-00783-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Baeza Garcia, A. et al. Neutralization of the plasmodium-encoded MIF ortholog confers protective immunity against malaria infection. Nat. Commun. 9, 2714 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30006528</ArticleId><ArticleId IdType="pmc">6045615</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-05041-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganley, M. et al. mRNA vaccine against malaria tailored for liver-resident memory T cells. Nat. Immunol. 24, 1487–1498 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37474653</ArticleId><ArticleId IdType="doi">10.1038/s41590-023-01562-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Battle, K. E. et al. Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modelling study. Lancet 394, 332–343 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31229233</ArticleId><ArticleId IdType="pmc">6675736</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(19)31096-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Krotoski, W. A. et al. Demonstration of hypnozoites in sporozoite-transmitted Plasmodium vivax infection. Am. J. Trop. Med. Hyg. 31, 1291–1293 (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">6816080</ArticleId><ArticleId IdType="doi">10.4269/ajtmh.1982.31.1291</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkeaw, N. et al. A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax. NPJ Vaccines 8, 187 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">38092803</ArticleId><ArticleId IdType="pmc">10719277</ArticleId><ArticleId IdType="doi">10.1038/s41541-023-00786-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahl, K. et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol. Ther. 25, 1316–1327 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28457665</ArticleId><ArticleId IdType="pmc">5475249</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2017.03.035</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi, N. et al. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat. Commun. 9, 3361 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30135514</ArticleId><ArticleId IdType="pmc">6105651</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-05482-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Laczko, D. et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity 53, 724–732 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32783919</ArticleId><ArticleId IdType="pmc">7392193</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2020.07.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava, K. et al. SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase. Immunity 57, 587–599 (2024). A longitudinal study describing the kinetics of SARS-CoV-2 spike antibody kinetics after COVID-19 mRNA vaccination through induction, waning and stabilization phases.</Citation><ArticleIdList><ArticleId IdType="pubmed">38395697</ArticleId><ArticleId IdType="pmc">11066813</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2024.01.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapin-Bardales, J., Gee, J. &amp; Myers, T. Reactogenicity following receipt of mRNA-based COVID-19 vaccines. JAMA 325, 2201–2202 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33818592</ArticleId><ArticleId IdType="doi">10.1001/jama.2021.5374</ArticleId></ArticleIdList></Reference><Reference><Citation>Reusch, J. et al. Inability to work following COVID-19 vaccination-a relevant aspect for future booster vaccinations. Public Health 222, 186–195 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37562083</ArticleId><ArticleId IdType="doi">10.1016/j.puhe.2023.07.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaggers, J. &amp; Wolfson, A. R. mRNA COVID-19 vaccine anaphylaxis: epidemiology, risk factors, and evaluation. Curr. Allergy Asthma Rep. 23, 195–200 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36689047</ArticleId><ArticleId IdType="pmc">9869308</ArticleId><ArticleId IdType="doi">10.1007/s11882-023-01065-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Oster, M. E. et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA 327, 331–340 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35076665</ArticleId><ArticleId IdType="pmc">8790664</ArticleId><ArticleId IdType="doi">10.1001/jama.2021.24110</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumenthal, K. G. et al. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2. N. Engl. J. Med. 384, 1273–1277 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33657292</ArticleId><ArticleId IdType="doi">10.1056/NEJMc2102131</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen, J. Skin side effects stymie advance of HIV vaccine. Science 383, 1044 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38452071</ArticleId><ArticleId IdType="doi">10.1126/science.adp0477</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitounis, D., Jacquinet, E., Rogers, M. A. &amp; Amiji, M. M. Strategies to reduce the risks of mRNA drug and vaccine toxicity. Nat. Rev. Drug Discov. 23, 281–300 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38263456</ArticleId><ArticleId IdType="doi">10.1038/s41573-023-00859-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy, I. et al. Correlation between adverse events and antibody titers among healthcare workers vaccinated with BNT162b2 mRNA COVID-19 vaccine. Vaccines 10, 1220 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36016109</ArticleId><ArticleId IdType="pmc">9412348</ArticleId><ArticleId IdType="doi">10.3390/vaccines10081220</ArticleId></ArticleIdList></Reference><Reference><Citation>Elizalde, M. U., Eguinoa, F. J. G., de Las Huertas, A. G. L., Jimenez-Gonzalez, M. &amp; Ramirez, E. Myocarditis and pericarditis risk with mRNA COVID-19 vaccination compared to unvaccinated individuals: a retrospective cohort study in a Spanish Tertiary Hospital. Biomed. Pharmacother. 171, 116181 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38262150</ArticleId><ArticleId IdType="doi">10.1016/j.biopha.2024.116181</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer, F. The human antibody response to influenza A virus infection and vaccination. Nat. Rev. Immunol. 19, 383–397 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30837674</ArticleId><ArticleId IdType="doi">10.1038/s41577-019-0143-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer, F. SARS-CoV-2 vaccines in development. Nature 586, 516–527 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32967006</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2798-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhavsar, D. et al. Mucosal antibody responses to SARS-CoV-2 booster vaccination and breakthrough infection. mBio 14, e0228023 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">38092666</ArticleId><ArticleId IdType="doi">10.1128/mbio.02280-23</ArticleId></ArticleIdList></Reference><Reference><Citation>Havervall, S. et al. Anti-spike mucosal IgA protection against SARS-CoV-2 omicron infection. N. Engl. J. Med. 387, 1333–1336 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36103621</ArticleId><ArticleId IdType="doi">10.1056/NEJMc2209651</ArticleId></ArticleIdList></Reference><Reference><Citation>Marking, U. et al. 7-Month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection. Lancet Infect. Dis. 23, 150–152 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36640796</ArticleId><ArticleId IdType="pmc">9833832</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(22)00834-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh-Mohamed, S. et al. Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection. Mucosal Immunol. 15, 799–808 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35468942</ArticleId><ArticleId IdType="pmc">9037584</ArticleId><ArticleId IdType="doi">10.1038/s41385-022-00511-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, S., Yeung, K. K. &amp; Watts, T. H. Tissue-resident memory T cells in protective immunity to influenza virus. Curr. Opin. Virol. 65, 101397 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38458064</ArticleId><ArticleId IdType="doi">10.1016/j.coviro.2024.101397</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, M. Z. M. &amp; Wakim, L. M. Tissue resident memory T cells in the respiratory tract. Mucosal Immunol. 15, 379–388 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34671115</ArticleId><ArticleId IdType="doi">10.1038/s41385-021-00461-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Ndeupen, S. et al. The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience 24, 103479 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34841223</ArticleId><ArticleId IdType="pmc">8604799</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2021.103479</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, B. et al. Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-023-01082-6 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41551-023-01082-6</ArticleId><ArticleId IdType="pubmed">38082180</ArticleId><ArticleId IdType="pmc">11162325</ArticleId></ArticleIdList></Reference><Reference><Citation>Künzli, M. et al. Route of self-amplifying mRNA vaccination modulates the establishment of pulmonary resident memory CD8 and CD4 T cells. Sci. Immunol. 7, eadd3075 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36459542</ArticleId><ArticleId IdType="pmc">9832918</ArticleId><ArticleId IdType="doi">10.1126/sciimmunol.add3075</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato, A., Hulse, K. E., Tan, B. K. &amp; Schleimer, R. P. B-lymphocyte lineage cells and the respiratory system. J. Allergy Clin. Immunol. 131, 933–957 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23540615</ArticleId><ArticleId IdType="pmc">3628816</ArticleId><ArticleId IdType="doi">10.1016/j.jaci.2013.02.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer, F. et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N. Engl. J. Med. 384, 1372–1374 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33691060</ArticleId><ArticleId IdType="doi">10.1056/NEJMc2101667</ArticleId></ArticleIdList></Reference><Reference><Citation>Carreño, J. M., Singh, G., Simon, V. &amp; Krammer, F.; PVI Study Group. Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies. Lancet Microbe 4, e569 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37141905</ArticleId><ArticleId IdType="doi">10.1016/S2666-5247(23)00118-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Chieh-Yu, L. et al. Prototype mRNA vaccines imprint broadly neutralizing human serum antibodies after Omicron variant-matched boosting. Preprint at bioRxiv https://doi.org/10.1101/2024.01.03.574018 (2024).</Citation></Reference><Reference><Citation>Alsoussi, W. B. et al. SARS-CoV-2 omicron boosting induces de novo B cell response in humans. Nature 617, 592–598 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37011668</ArticleId><ArticleId IdType="doi">10.1038/s41586-023-06025-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer, F. &amp; Ellebedy, A. H. Variant-adapted COVID-19 booster vaccines. Science 382, 157–159 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37824671</ArticleId><ArticleId IdType="doi">10.1126/science.adh2712</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortorici, M. A. et al. Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans. Immunity 57, 904–911 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38490197</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2024.02.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonville, J. M. et al. Antibody landscapes after influenza virus infection or vaccination. Science 346, 996–1000 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25414313</ArticleId><ArticleId IdType="pmc">4246172</ArticleId><ArticleId IdType="doi">10.1126/science.1256427</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis, T. On the doctrine of original antigenic sin. Proc. Natl Acad. Sci. USA 104, 572–578 (1960).</Citation></Reference><Reference><Citation>Wrammert, J. et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667–671 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18449194</ArticleId><ArticleId IdType="pmc">2515609</ArticleId><ArticleId IdType="doi">10.1038/nature06890</ArticleId></ArticleIdList></Reference><Reference><Citation>Mankarious, S. et al. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J. Lab. Clin. Med. 112, 634–640 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3183495</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Hoogen, L. L. et al. SARS-CoV-2 Spike S1-specific IgG kinetic profiles following mRNA or vector-based vaccination in the general Dutch population show distinct kinetics. Sci. Rep. 12, 5935 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35396570</ArticleId><ArticleId IdType="pmc">8990276</ArticleId><ArticleId IdType="doi">10.1038/s41598-022-10020-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Han, X. et al. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines. Nat. Nanotechnol. 18, 1105–1114 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37365276</ArticleId><ArticleId IdType="doi">10.1038/s41565-023-01404-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Mettelman, R. C. et al. Baseline innate and T cell populations are correlates of protection against symptomatic influenza virus infection independent of serology. Nat. Immunol. 24, 1511–1526 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37592015</ArticleId><ArticleId IdType="pmc">10566627</ArticleId><ArticleId IdType="doi">10.1038/s41590-023-01590-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette, A., Sidney, J. &amp; Crotty, S. T cell responses to SARS-CoV-2. Annu. Rev. Immunol. 41, 343–373 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36750314</ArticleId><ArticleId IdType="doi">10.1146/annurev-immunol-101721-061120</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi, N. et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J. Exp. Med. 215, 1571–1588 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29739835</ArticleId><ArticleId IdType="pmc">5987916</ArticleId><ArticleId IdType="doi">10.1084/jem.20171450</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Z. et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell 185, 2434–2451 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35764089</ArticleId><ArticleId IdType="pmc">9135677</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2022.05.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Painter, M. M. et al. Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV-2 breakthrough infection. Nat. Immunol. 24, 1711–1724 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37735592</ArticleId><ArticleId IdType="doi">10.1038/s41590-023-01613-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer, C. D. et al. GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults. Nat. Commun. 14, 3274 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37280238</ArticleId><ArticleId IdType="pmc">10242235</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-39053-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao, L. et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat. Biotechnol. 37, 1174–1185 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31570898</ArticleId><ArticleId IdType="doi">10.1038/s41587-019-0247-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Carreno, J. M. et al. mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations. Vaccine 40, 6114–6124 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36115801</ArticleId><ArticleId IdType="pmc">9474432</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2022.08.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju, Y. et al. Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines. Nat. Rev. Immunol. 23, 135–136 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">9764299</ArticleId><ArticleId IdType="doi">10.1038/s41577-022-00825-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju, Y. et al. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. ACS Nano 16, 11769–11780 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35758934</ArticleId><ArticleId IdType="doi">10.1021/acsnano.2c04543</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, H. et al. Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles in rats. NPJ Vaccines 8, 169 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37919316</ArticleId><ArticleId IdType="pmc">10622525</ArticleId><ArticleId IdType="doi">10.1038/s41541-023-00766-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, T. C., Chen, B. M., Wu, J. Y., Cheng, T. L. &amp; Roffler, S. Impact of anti-PEG antibody affinity on accelerated blood clearance of pegylated epoetin beta in mice. Biomed. Pharmacother. 146, 112502 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34891120</ArticleId><ArticleId IdType="doi">10.1016/j.biopha.2021.112502</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Q. et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe 32, 315–321 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38377995</ArticleId><ArticleId IdType="pmc">10948033</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2024.01.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. N. Engl. J. Med. 383, 1920–1931 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32663912</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2022483</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh, E. E. et al. Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N. Engl. J. Med. 383, 2439–2450 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33053279</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2027906</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, A. et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat. Med. 27, 2025–2031 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34526698</ArticleId><ArticleId IdType="pmc">8604720</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01527-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerdil, C. The annual production cycle for influenza vaccine. Vaccine 21, 1776–1779 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12686093</ArticleId><ArticleId IdType="doi">10.1016/S0264-410X(03)00071-9</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong, J. C., Beyer, W. E., Palache, A. M., Rimmelzwaan, G. F. &amp; Osterhaus, A. D. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J. Med. Virol. 61, 94–99 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10745239</ArticleId><ArticleId IdType="doi">10.1002/(SICI)1096-9071(200005)61:1&lt;94::AID-JMV15&gt;3.0.CO;2-C</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, H. et al. H3N2 mismatch of 2014-15 Northern hemisphere influenza vaccines and head-to-head comparison between human and ferret antisera derived antigenic maps. Sci. Rep. 5, 15279 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26472175</ArticleId><ArticleId IdType="pmc">4607887</ArticleId><ArticleId IdType="doi">10.1038/srep15279</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotkin, S., Robinson, J. M., Cunningham, G., Iqbal, R. &amp; Larsen, S. The complexity and cost of vaccine manufacturing — an overview. Vaccine 35, 4064–4071 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28647170</ArticleId><ArticleId IdType="pmc">5518734</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2017.06.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly, D. F. &amp; Rappuoli, R. Reverse vaccinology and vaccines for serogroup B Neisseria meningitidis. Adv. Exp. Med. Biol. 568, 217–223 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16107075</ArticleId><ArticleId IdType="doi">10.1007/0-387-25342-4_15</ArticleId></ArticleIdList></Reference><Reference><Citation>Rappuoli, R., Bottomley, M. J., D’Oro, U., Finco, O. &amp; De Gregorio, E. Reverse vaccinology 2.0: human immunology instructs vaccine antigen design. J. Exp. Med. 213, 469–481 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27022144</ArticleId><ArticleId IdType="pmc">4821650</ArticleId><ArticleId IdType="doi">10.1084/jem.20151960</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzau, V. J., Balatbat, C. A. &amp; Offodile, A. C. Closing the global vaccine equity gap: equitably distributed manufacturing. Lancet 399, 1924–1926 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35533706</ArticleId><ArticleId IdType="pmc">9075857</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(22)00793-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Privor-Dumm, L. et al. Vaccine access, equity and justice: COVID-19 vaccines and vaccination. BMJ Glob. Health 8 https://doi.org/10.1136/bmjgh-2023-011881 (2023).</Citation></Reference><Reference><Citation>Krammer, F. The role of vaccines in the COVID-19 pandemic: what have we learned? Semin. Immunopathol. 45, 451–468 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">37436465</ArticleId><ArticleId IdType="doi">10.1007/s00281-023-00996-2</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dijk, R. J. L. &amp; Lo, C. Y.-P. The effect of Chinese vaccine diplomacy during COVID-19 in the Philippines and Vietnam: a multiple case study from a soft power perspective. Hum. Soc. Sci. Commun. 10, 687 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1057/s41599-023-02073-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, M. et al. Lyophilization process optimization and molecular dynamics simulation of mRNA-LNPs for SARS-CoV-2 vaccine. NPJ Vaccines 8, 153 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37813912</ArticleId><ArticleId IdType="pmc">10562438</ArticleId><ArticleId IdType="doi">10.1038/s41541-023-00732-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Muramatsu, H. et al. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine. Mol. Ther. 30, 1941–1951 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35131437</ArticleId><ArticleId IdType="pmc">8815268</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2022.02.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirane, D. et al. Development of an alcohol dilution-lyophilization method for the preparation of mRNA-LNPs with improved storage stability. Pharmaceutics 15, 1819 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37514007</ArticleId><ArticleId IdType="pmc">10383539</ArticleId><ArticleId IdType="doi">10.3390/pharmaceutics15071819</ArticleId></ArticleIdList></Reference><Reference><Citation>Vander Straeten, A. et al. A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines. Nat. Biotechnol. 42, 510–517 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-023-01774-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Voigt, E. A. et al. A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability. NPJ Vaccines 7, 136 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36323666</ArticleId><ArticleId IdType="pmc">9628444</ArticleId><ArticleId IdType="doi">10.1038/s41541-022-00549-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxmen, A. Unseating big pharma: the radical plan for vaccine equity. Nature 607, 226–233 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35831606</ArticleId><ArticleId IdType="doi">10.1038/d41586-022-01898-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparrow, E. et al. Leveraging mRNA platform technology to accelerate development of vaccines for some emerging and neglected tropical diseases through local vaccine production. Front. Trop. Dis. 3, 844039 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fitd.2022.844039</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutt, D., Mazzucato, M. &amp; Torreele, E. An mRNA technology transfer programme and economic sustainability in health care. Bull. World Health Organ. 102, 344–351 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38680466</ArticleId><ArticleId IdType="pmc">11046156</ArticleId><ArticleId IdType="doi">10.2471/BLT.24.291388</ArticleId></ArticleIdList></Reference><Reference><Citation>Adepoju, P. Moderna stalls on African vaccine manufacturing plans. Lancet 403, 1617 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38679023</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(24)00858-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi, N. et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat. Commun. 8, 14630 (2017). The first study demonstrating that the nucleoside-modified mRNA-LNP platform can be used for passive immunotherapy in preclinical studies.</Citation><ArticleIdList><ArticleId IdType="pubmed">28251988</ArticleId><ArticleId IdType="pmc">5337964</ArticleId><ArticleId IdType="doi">10.1038/ncomms14630</ArticleId></ArticleIdList></Reference><Reference><Citation>Thran, M. et al. mRNA mediates passive vaccination against infectious agents, toxins, and tumors. EMBO Mol. Med. 9, 1434–1447 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28794134</ArticleId><ArticleId IdType="pmc">5623855</ArticleId><ArticleId IdType="doi">10.15252/emmm.201707678</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiwari, P. M. et al. Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection. Nat. Commun. 9, 3999 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30275522</ArticleId><ArticleId IdType="pmc">6167369</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-06508-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Kose, N. et al. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Sci. Immunol. 4, eaaw6647 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31101672</ArticleId><ArticleId IdType="pmc">6629435</ArticleId><ArticleId IdType="doi">10.1126/sciimmunol.aaw6647</ArticleId></ArticleIdList></Reference><Reference><Citation>August, A. et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat. Med. 27, 2224–2233 (2021). The first study demonstrating that the nucleoside-modified mRNA-LNP platform can be successfully used for passive immunotherapy in humans.</Citation><ArticleIdList><ArticleId IdType="pubmed">34887572</ArticleId><ArticleId IdType="pmc">8674127</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01573-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hoecke, L. et al. mRNA encoding a bispecific single domain antibody construct protects against influenza A virus infection in mice. Mol. Ther. Nucl. Acids 20, 777–787 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2020.04.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Erasmus, J. H. et al. Intramuscular delivery of replicon RNA encoding ZIKV-117 human monoclonal antibody protects against zika virus infection. Mol. Ther. Methods Clin. Dev. 18, 402–414 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32695842</ArticleId><ArticleId IdType="pmc">7363633</ArticleId><ArticleId IdType="doi">10.1016/j.omtm.2020.06.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, J. Q. et al. Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice. Signal. Transduct. Target. Ther. 6, 369 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34697295</ArticleId><ArticleId IdType="pmc">8543430</ArticleId><ArticleId IdType="doi">10.1038/s41392-021-00783-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y. N. et al. Intranasal delivery of replicating mRNA encoding hACE2-targeting antibody against SARS-CoV-2 Omicron infection in the hamster. Antivir. Res. 209, 105507 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36565755</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2022.105507</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, B. et al. A single dose of anti-HBsAg antibody-encoding mRNA-LNPs suppressed HBsAg expression: a potential cure of chronic hepatitis B virus infection. mBio 13, e0161222 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35862767</ArticleId><ArticleId IdType="doi">10.1128/mbio.01612-22</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng, Y. Q. et al. Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters. Cell Res. 32, 375–382 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35210606</ArticleId><ArticleId IdType="pmc">8866932</ArticleId><ArticleId IdType="doi">10.1038/s41422-022-00630-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucker, E. M., Thiele-Suess, C., Baumhof, P. &amp; Hooper, J. W. Lipid nanoparticle delivery of unmodified mRNAs encoding multiple monoclonal antibodies targeting poxviruses in rabbits. Mol. Ther. Nucleic Acids 28, 847–858 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35664703</ArticleId><ArticleId IdType="pmc">9149018</ArticleId><ArticleId IdType="doi">10.1016/j.omtn.2022.05.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanan, E. et al. Rational design and in vivo characterization of mRNA-encoded broadly neutralizing antibody combinations against HIV-1. Antibodies 11, 67 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36412833</ArticleId><ArticleId IdType="pmc">9680504</ArticleId><ArticleId IdType="doi">10.3390/antib11040067</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanover, D. et al. Nebulized mRNA-encoded antibodies protect hamsters from SARS-CoV-2 infection. Adv. Sci. 9, e2202771 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202202771</ArticleId></ArticleIdList></Reference><Reference><Citation>Deal, C. E. et al. An mRNA-based platform for the delivery of pathogen-specific IgA into mucosal secretions. Cell Rep. Med. 4, 101253 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37918405</ArticleId><ArticleId IdType="pmc">10694625</ArticleId><ArticleId IdType="doi">10.1016/j.xcrm.2023.101253</ArticleId></ArticleIdList></Reference><Reference><Citation>Thran, M. et al. Co-administration of an effector antibody enhances the half-life and therapeutic potential of RNA-encoded nanobodies. Sci. Rep. 13, 14632 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37670025</ArticleId><ArticleId IdType="pmc">10480410</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-41092-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, X. et al. Circular RNA: an emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines. J. Control. Rel. 348, 84–94 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2022.05.043</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesselhoeft, R. A., Kowalski, P. S. &amp; Anderson, D. G. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat. Commun. 9, 2629 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29980667</ArticleId><ArticleId IdType="pmc">6035260</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-05096-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesselhoeft, R. A. et al. RNA circularization diminishes immunogenicity and can extend translation duration in vivo. Mol. Cell 74, 508–520 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30902547</ArticleId><ArticleId IdType="pmc">6724735</ArticleId><ArticleId IdType="doi">10.1016/j.molcel.2019.02.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, R. et al. Engineering circular RNA for enhanced protein production. Nat. Biotechnol. 41, 262–272 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">35851375</ArticleId><ArticleId IdType="doi">10.1038/s41587-022-01393-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu, L. et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell 185, 1728–1744 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35460644</ArticleId><ArticleId IdType="pmc">8971115</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2022.03.044</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito, S. et al. Monoclonal antibodies for prophylaxis and therapy of respiratory syncytial virus, SARS-CoV-2, human immunodeficiency virus, rabies and bacterial infections: an update from the World Association of Infectious Diseases and Immunological Disorders and the Italian Society of Antinfective Therapy. Front. Immunol. 14, 1162342 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37256125</ArticleId><ArticleId IdType="pmc">10226646</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1162342</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung, C. et al. Expanding the reach of monoclonal antibodies: a review of synthetic nucleic acid delivery in immunotherapy. Antibodies 12, 46 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37489368</ArticleId><ArticleId IdType="pmc">10366852</ArticleId><ArticleId IdType="doi">10.3390/antib12030046</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitley, J. et al. Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials. Transl. Res. 242, 38–55 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34871810</ArticleId><ArticleId IdType="doi">10.1016/j.trsl.2021.11.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingels, J. et al. Small-scale manufacturing of neoantigen-encoding messenger RNA for early-phase clinical trials. Cytotherapy 24, 213–222 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34696961</ArticleId><ArticleId IdType="doi">10.1016/j.jcyt.2021.08.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa, S. S., Prazeres, D. M. F., Azevedo, A. M. &amp; Marques, M. P. C. mRNA vaccines manufacturing: challenges and bottlenecks. Vaccine 39, 2190–2200 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33771389</ArticleId><ArticleId IdType="pmc">7987532</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2021.03.038</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb, C. et al. Current status and future perspectives on MRNA drug manufacturing. Mol. Pharm. 19, 1047–1058 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35238565</ArticleId><ArticleId IdType="doi">10.1021/acs.molpharmaceut.2c00010</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>